"By exciting the Q-neurons in the hypothalamus, body temperature and metabolic functions drop significantly, allowing one to transition into a hibernation state spontaneously and safely." The doctor ...

Revolutionary technology has rejuvenated rats using exosomes from young pigs. The potential for translation to humans beckons us, but progress has been slow. The medical field, including aging ...

MC4R pathway restoration with daily subcutaneous setmelanotide achieved a −16.5% least-squares mean BMI change versus +3.3% with placebo at 52 weeks (P < .001). Clinically relevant response rates ...

Nominations for the 78th Emmy Awards were announced today from the Wolf Theatre in the Saban Media Center. The live ceremony was hosted by Emmy winner Liza Colón-Zayas (The Bear) and Emmy winner Jeff ...

A phase 2 trial of setmelanotide, a melanocortin-4 receptor agonist, showed substantial weight loss in patients with acquired hypothalamic obesity, but additional data are needed. We conducted a phase ...

DC Studios and Warner Bros. Animation are partnering on a series adaptation of Scott Snyder and Nick Dragotta’s best selling DC comic book series Absolute Batman. The partners announced the upcoming ...

Hypothalamic obesity (HyOb) develops when damage to the hypothalamus — from brain tumors, traumatic brain injury, radiation therapy, or stroke — disrupts how your body regulates appetite and ...

Hypothalamic obesity (HyOb) is a rare type of obesity caused by damage to the hypothalamus, the brain region that regulates hunger, metabolism, and energy balance. This damage disrupts your body’s ...

Credit: Rhythm Pharmaceuticals. The melanocortin 4 receptor agonist setmelanotide is now FDA approved for weight management in adults and children with acquired hypothalamic obesity. Clinical trial ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved an expanded indication for setmelanotide for acquired hypothalamic obesity. The drug conferred ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population estimated at ~10,000 in the US and characterized by severe hyperphagia.